ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Inclusion Criteria:

1. Ability to understand and the willingness to sign a written informed consentdocument

2. Signed Informed Consent

3. Confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma asIW-CLL 2008 criteria (Hallek et al, 2008) with biopsy proven transformation todiffuse large B cell lymphoma (DLBCL), consistent with Richter's Syndrome

4. Age greater than or equal to 18 years

5. ECOG performance status <= 2

6. Patients must meet the following hematologic criteria at screening, unless they havesignificant bone marrow involvement of their malignancy confirmed on biopsy:

• Absolute neutrophil count >=1000 cells/mm3 (1.0 x 10^9/L).

• Platelet count >= 50,000 cells/mm3 (50 x 10^9/L) within 7 days of screening

• Total hemoglobin > 9 g/dL (without transfusion support, unless anemia is due tomarrow involvement of CLL)

7. Subject must have adequate coagulation, renal, and hepatic function, per laboratoryreference range at screening as follows:

• Activated partial thromboplastin time (aPTT) and International normalized ratio (INR) > 1.5 x ULN for patients not receiving therapeutic anticoagulation;

• Creatinine <= 1.5 x ULN or creatinine clearance >= 50 mL/min based onCockcroft-Gault formula;

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 ×ULN;

• Bilirubin <= 1.5 × ULN;

8. Subjects with Gilbert's Syndrome or resolving autoimmunohemolytic anemia may have abilirubin up to 3.0 × ULN and are still eligible

9. Negative pregnancy tests as verified by the investigator prior to starting anytreatment.

Exclusion Criteria:

1. Prior treatment for Richter transformation.

2. Prior treatment with obinutuzumab anti PD-1 or PDL-1 antibodies.

3. Prior treatment with venetoclax.

4. Hypersensitivity to obinutuzumab, venetoclax or atezolizumab or their formulationexcipients.

5. Patients with the Hodgkin variant transformation of CLL.

6. Prolymphocytic transformation.

7. Patients with a previous history of indolent B cell malignancies other than CLL.

8. History of other malignancy other than CLL and Richter syndrome that could affectcompliance with the protocol or interpretation of results with the exception of:

9. Patients with curatively treated basal or squamous cell carcinoma or stage 1melanoma of the skin or in situ carcinoma of the cervix

10. Patients with a malignancy that has been treated with surgery alone withcurative intent. Individuals in documented remission without treatment for > 2years prior to enrollment may be included at the discretion of theSponsor-Investigator.

11. Low-risk prostate cancer on active surveillance.

12. Evidence of significant, uncontrolled concomitant diseases that could affectcompliance with the protocol or interpretation of results or that could increaserisk to the patient, including renal disease that would preclude chemotherapyadministration or pulmonary disease (including obstructive pulmonary disease andhistory of bronchospasm).

13. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episodeof infection requiring treatment with IV antibiotics or hospitalization (relating tothe completion of the course of antibiotics) within 4 weeks prior to Cycle1, Day1.

14. Clinically significant history of liver disease, including autoimmune hepatitis,current alcohol abuse, or cirrhosis.

15. Presence of positive PCR for hepatitis B, hepatitis C or positive hepatitis Bsurface antigen.

16. Patients with uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia.

17. History of active autoimmune disease.

18. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitisobliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of activepneumonitis per chest CT scan at screening. History of radiation pneumonitis in theradiation field (fibrosis) is allowed.

19. Concurrent systemic immunosuppressant therapy within 28 days of the first dose ofstudy drug.

20. Corticosteroids are allowed, but must be dosed at prednisone 30 mg (or equivalent)or lower prior to the start of chemotherapy.

21. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of studydrug.

22. Known bleeding disorders (eg, von Willebrand's disease) or hemophilia.

23. Requires anticoagulation with vitamin K antagonists (e.g. phenprocoumon, warfarin)

24. History of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) oractive hepatitis B virus (HBV).

25. Major surgery within 4 weeks of first dose of study drug.

26. Any life-threatening illness, medical condition, or organ system dysfunction that,in the investigator's opinion, could compromise the subject's safety or put thestudy outcomes at undue risk.

27. Patients with infections requiring IV treatment (Grade 3 or 4) within the last 2months prior to enrolment.